Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Final Trade: WYNN, CAR, JD, NVO
06:21pm, Monday, 15'th Sep 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: The Market Is Giving Us A Free Lunch
12:53pm, Monday, 15'th Sep 2025
Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underlying
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Why Novo Nordisk Stock Popped Today
11:34am, Monday, 15'th Sep 2025
Novo Nordisk (NVO 1.84%) -- the original Ozempic stock -- is getting a boost from a Financial Times report this morning highlighting positive results from two weight loss trials using increased dosage
Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.
10:50am, Monday, 15'th Sep 2025
Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Novo (NVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired s
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO).
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
12:40pm, Saturday, 13'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffe
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
06:30am, Saturday, 13'th Sep 2025
The oral GLP-1 segment is entering a pivotal stage, with major growth anticipated from 2026 onward. Patient preference for oral pills over injectables is strong, making ease of use a key driver for fu
Novo Nordisk: GLP-1's Concerns Are Overblown
04:41am, Saturday, 13'th Sep 2025
Novo continues to face U.S. market share pressure from Eli Lilly's Tirzepatide based GLP-1 and off-label semaglutide, but retains strong international GLP-1 dominance with 71% market share outside the
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
06:46pm, Friday, 12'th Sep 2025
Novo Nordisk (NVO) reached $54.87 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.
